Related Experiment Video
Updated: Aug 18, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of
Francesco Costa1, Claudio Montalto2, Mattia Branca3
1Department of Biomedical and Dental Sciences and Morphological and Functional Imaging, University of Messina, A.O.U. Policlinic 'G. Martino', Messina 98100, Italy.
Insights
Shorter dual antiplatelet therapy (DAPT) durations of 1 or 3 months significantly reduce bleeding and cardiovascular mortality in high bleeding risk patients after percutaneous coronary intervention. These abbreviated regimens do not increase ischemic event risk compared to standard longer durations.
Area of Science:
- Cardiology
- Interventional Cardiology
- Clinical Trials
Background:
- Optimal duration of dual antiplatelet therapy (DAPT) post-percutaneous coronary intervention (PCI) for high bleeding risk (HBR) patients remains uncertain.
- Existing evidence is synthesized to evaluate abbreviated DAPT regimens in HBR populations.
Approach:
- A systematic review and meta-analysis of randomized clinical trials was conducted.
- Included trials compared abbreviated (1 or 3 months) DAPT with standard (≥6 months) DAPT in HBR patients without need for oral anticoagulation.
- Data from 11 trials involving 9006 patients were analyzed.
Key Points:
- Abbreviated DAPT significantly reduced major or clinically relevant non-major bleeding (RR: 0.76) and major bleeding (RR: 0.80).
- Cardiovascular mortality was also lower with abbreviated DAPT (RR: 0.79).
- No significant differences were observed in all-cause mortality, major adverse cardiovascular events, myocardial infarction, or stent thrombosis.
Conclusions:
- In HBR patients undergoing PCI, 1- or 3-month DAPT regimens are associated with reduced bleeding and cardiovascular mortality.
- These shorter DAPT durations do not appear to increase ischemic event risk compared to standard ≥6-month regimens.
- Findings were consistent across different HBR definitions and clinical presentations.
Aims:
The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study, using the totality of existing evidence, evaluated the impact of an abbreviated DAPT regimen in HBR patients.
Methods And Results:
A systematic review and meta-analysis was performed to search randomized clinical trials comparing abbreviated [i.e. very-short (1 month) or short (3 months)] with standard (≥6 months) DAPT in HBR patients without indication for oral anticoagulation. A total of 11 trials, including 9006 HBR patients, were included. Abbreviated DAPT reduced major or clinically relevant non-major bleeding [risk ratio (RR): 0.76, 95% confidence interval (CI): 0.61-0.94; I2 = 28%], major bleeding (RR: 0.80, 95% CI: 0.64-0.99, I2 = 0%), and cardiovascular mortality (RR: 0.79, 95% CI: 0.65-0.95, I2 = 0%) compared with standard DAPT. No difference in all-cause mortality, major adverse cardiovascular events, myocardial infarction, or stent thrombosis was observed. Results were consistent, irrespective of HBR definition and clinical presentation.
Conclusion:
In HBR patients undergoing PCI, a 1- or 3-month abbreviated DAPT regimen was associated with lower bleeding and cardiovascular mortality, without increasing ischaemic events, compared with a ≥6-month DAPT regimen.
Study Registration:
PROSPERO registration number CRD42021284004.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis III: Interprofessional Care

